NEW YORK (TheStreet) -- It's always interesting to see how health care investors live in perpetual fear of the long-term health of their companies. This is regardless of whether the signs of slowing growth have emerged.
While some companies can provoke this terror by under-investing in their product pipelines, which is essentially their lifeblood, others look to offset this fear with extensive cost-cutting measures (if they care to impress the Street). Even with the recent patent expiration of its drug Plavix, these have never been glowing issues for Bristol-Myers Squibb (BMY), whose stock is up more than 50% year-to-date.
In that regard, I don't believe the company's management has gotten the credit they rightfully deserve. Not only does Bristol-Myers continue to invest in growth opportunities, but the company has consistently taken the best punches from giants like Johnson & Johnson (JNJ), who recently brought to market Xarelto to compete with Bristol-Myers' new blockbuster drug Eliquis, an anticoagulant for preventing blood clots.
The question now: To what extent management can sustain this incredible run? As I've said, not only has the stock shot up more than 50% on the year, but even since the company picked off its partner ZymoGenetics three years ago for $9.75 per share in cash, shares of Bristol-Myers have soared more than 110%. As expected, bears have gotten anxious and have raised caution flags, while citing things like "valuation exuberance."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts